Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Best Buy Co Inc (BBY) vs Pfizer Inc (PFE) Price & Performance

Best Buy Co IncTrade
Pfizer IncTrade

Price performance (Past 24H)

Key statistics

Best Buy Co Inc vs Pfizer Inc — how do they compare? Best Buy Co Inc trades at $83.61 (market cap $17.70B), while Pfizer Inc trades at $24.26 (market cap $138.21B). The key difference: Pfizer Inc is far larger — about 7.8× Best Buy Co Inc's market cap, and Pfizer Inc pays the higher dividend (7.09%). Which is the better fit depends on your goals.

BBYPFE
Market Cap
$17.70B$138.21B
Sector
Consumer CyclicalHealth
52-Week High
$84.00$28.56
52-Week Low
$55.52$23.29
Enterprise Value
$20.08B$188.87B
Dividend Yield
4.57%7.09%
Volume
29,869,932

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Best Buy Co Inc

Best Buy (BBY) trades at $81.65, down 1.39% on the day, with a bullish technical outlook and strong recent earnings beats. The stock shows robust profitability with a 39.1% ROE and trades at attractive valuations (P/E 15.12, P/S 0.41). Recent news highlights leadership changes and strategic shifts toward higher-margin businesses like marketplace and retail media, supported by new product launches such as RGB LED TVs and Meta VR partnerships.

The outlook is cautiously optimistic with a consensus price target of $82.17 offering modest upside. Key opportunities include dividend yield near 5% and earnings momentum, while risks involve revenue declines, competitive pressures, and macroeconomic sensitivity. Analyst sentiment is mixed with 34% buy ratings, reflecting balanced views on growth potential versus execution challenges.

Pfizer Inc

Pfizer (PFE) trades at $24.25, up 0.33% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported Q1 2026 EPS of $0.75, beating expectations, and maintains a dividend of $0.43 per share. Recent news highlights Pfizer's focus on its obesity and oncology pipeline, with key catalysts expected in 2026. Financials show revenue of $62.58B in 2025, with a net income margin of 11.83% and a P/E ratio of 18.69.

The outlook for Pfizer is mixed, with analyst consensus leaning toward Hold (58.98%) but a price target of $28.78 suggesting potential upside. Investment opportunities include a strong dividend yield and pipeline advancements, while risks involve patent cliffs and competitive pressures. The stock's current valuation appears reasonable, but execution on pipeline developments is critical for future growth.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Best Buy Co Inc

With $51.8 billion in fiscal 2022 sales, Best Buy is the largest pure-play consumer electronics retailer in the U.S., with roughly 10.6% share of the aggregate market and north of 40% share of offline sales, per our calculations, CTA industry, and Euromonitor data. The firm generates the bulk of its sales in-store, with mobile phones and tablets, computers, and appliances representing its three largest categories. Recent investments in e-commerce fulfillment, accelerated by the COVID-19 pandemic, have seen the U.S. e-commerce channel roughly double from prepandemic levels, with management estimating that it will represent a mid-30% proportion of sales moving forward.

Read more on BBY

About Pfizer Inc

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.

Read more on PFE